{
    "nctId": "NCT00193778",
    "briefTitle": "Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation",
    "officialTitle": "A Randomized Trial To Assess The Impact Of Loco-Regional Treatment On Survival Of Patients With Metastatic Breast Cancer At First Presentation",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer of the Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 350,
    "primaryOutcomeMeasure": "Overall survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic breast cancer at first presentation with an expected survival of at least one year\n\nExclusion Criteria:\n\n1. Patients who are not fit to receive anthracycline based chemotherapy.\n2. More than two visceral organ involvement.\n3. Multiple liver metastases with deranged liver function tests (SGOT/SGPT more than four times the upper normal limit).\n4. Locally static or progressive disease or systemically progressive disease as shown by repeat staging investigations guided by worsening symptoms.\n5. Ulceration/ fungation/ bleeding after completion of chemotherapy, which mandates surgery.\n6. Expected survival of less than six months after completion of chemotherapy.\n7. Unfit for anaesthesia due to metastatic disease.",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}